Brokers Offer Predictions for Atossa Genetics Q3 Earnings

Key Points

• HC Wainwright has revised its Q3 2025 earnings estimate for Atossa Genetics to ($0.07) per share, down from the previous estimate of ($0.06), indicating a weaker outlook for the company.
• Despite lowered earnings expectations, Craig Hallum upgraded Atossa Genetics to a "strong-buy" rating with a target price of $4.00, while Ascendiant Capital Markets raised their target price from $7.25 to $7.50.
• Atossa Genetics shares traded at $0.79, reflecting a market capitalization of $102.04 million and showing a one-year price range between $0.55 and $1.66.

Atossa Genetics Inc. (NASDAQ:ATOS - Free Report) - Analysts at HC Wainwright dropped their Q3 2025 earnings estimates for Atossa Genetics in a report released on Tuesday, August 12th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.07) per share for the quarter, down from their previous forecast of ($0.06). The consensus estimate for Atossa Genetics' current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Genetics' FY2025 earnings at ($0.26) EPS, FY2026 earnings at ($0.31) EPS, FY2027 earnings at ($0.28) EPS, FY2028 earnings at ($0.23) EPS and FY2029 earnings at ($0.18) EPS.

Atossa Genetics (NASDAQ:ATOS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.01).

Other equities research analysts have also recently issued research reports about the stock. Ascendiant Capital Markets upped their price objective on shares of Atossa Genetics from $7.25 to $7.50 and gave the stock a "buy" rating in a report on Friday, June 6th. Craig Hallum upgraded shares of Atossa Genetics to a "strong-buy" rating and set a $4.00 price objective on the stock in a report on Thursday, June 5th.

Atossa Genetics Trading Up 1.7%

ATOS traded up $0.01 during midday trading on Friday, reaching $0.79. The company's stock had a trading volume of 524,181 shares, compared to its average volume of 1,343,465. The firm has a market capitalization of $102.05 million, a price-to-earnings ratio of -3.43 and a beta of 0.92. Atossa Genetics has a 1 year low of $0.55 and a 1 year high of $1.66. The stock's 50-day moving average is $0.84 and its 200-day moving average is $0.79.

Institutional Investors Weigh In On Atossa Genetics

A number of institutional investors have recently made changes to their positions in ATOS. Hudson Bay Capital Management LP purchased a new stake in Atossa Genetics in the second quarter worth approximately $26,000. Millennium Management LLC purchased a new stake in Atossa Genetics in the fourth quarter worth approximately $28,000. Two Sigma Advisers LP boosted its holdings in Atossa Genetics by 214.1% in the fourth quarter. Two Sigma Advisers LP now owns 42,400 shares of the company's stock worth $40,000 after purchasing an additional 28,900 shares during the last quarter. Catalyst Funds Management Pty Ltd purchased a new stake in Atossa Genetics in the second quarter worth approximately $49,000. Finally, Wells Fargo & Company MN boosted its holdings in Atossa Genetics by 30.7% in the fourth quarter. Wells Fargo & Company MN now owns 71,720 shares of the company's stock worth $68,000 after purchasing an additional 16,853 shares during the last quarter. Hedge funds and other institutional investors own 12.74% of the company's stock.

Atossa Genetics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.